FusionNeoAntigen Logo

Home

Download

Statistics

Examples

Help

Contact

Terms of Use

Center for Computational Systems Medicine
leaf

Fusion Gene and Fusion Protein Summary

leaf

Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)

leaf

Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)

leaf

Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)

leaf

Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)

leaf

Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)

leaf

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)

leaf

Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)

leaf

Potential target of CAR-T therapy development

leaf

Information on the samples that have these potential fusion neoantigens

leaf

Fusion Protein Targeting Drugs - (Manual Curation)

leaf

Fusion Protein Related diseases - (Manual Curation)

Fusion Protein:CLU-PEBP1

Fusion Gene and Fusion Protein Summary

check button Fusion gene summary
Fusion partner gene informationFusion gene name: CLU-PEBP1
FusionPDB ID: 17456
FusionGDB2.0 ID: 17456
HgeneTgene
Gene symbol

CLU

PEBP1

Gene ID

1191

5037

Gene nameclusterinphosphatidylethanolamine binding protein 1
SynonymsAAG4|APO-J|APOJ|CLI|CLU1|CLU2|KUB1|NA1/NA2|SGP-2|SGP2|SP-40|TRPM-2|TRPM2HCNP|HCNPpp|HEL-210|HEL-S-34|HEL-S-96|PBP|PEBP|PEBP-1|RKIP
Cytomap

8p21.1

12q24.23

Type of geneprotein-codingprotein-coding
Descriptionclusterinaging-associated protein 4apolipoprotein Jcomplement cytolysis inhibitorcomplement lysis inhibitorcomplement-associated protein SP-40,40epididymis secretory sperm binding proteinku70-binding protein 1sulfated glycoprotein 2testosterone-rphosphatidylethanolamine-binding protein 1Raf kinase inhibitory proteinepididymis luminal protein 210epididymis secretory protein Li 34epididymis secretory protein Li 96hippocampal cholinergic neurostimulating peptideneuropolypeptide h3prostatic bi
Modification date2020032720200327
UniProtAcc

Q15846

Main function of 5'-partner protein:
.
Ensembl transtripts involved in fusion geneENST idsENST00000316403, ENST00000405140, 
ENST00000523500, ENST00000546343, 
ENST00000560366, 
ENST00000542939, 
ENST00000261313, 
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)* DoF score38 X 38 X 12=173286 X 5 X 4=120
# samples 497
** MAII scorelog2(49/17328*10)=-5.14417958860576
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
log2(7/120*10)=-0.777607578663552
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
Fusion gene context

PubMed: CLU [Title/Abstract] AND PEBP1 [Title/Abstract] AND fusion [Title/Abstract]

Fusion neoantigen context

PubMed: CLU [Title/Abstract] AND PEBP1 [Title/Abstract] AND neoantigen [Title/Abstract]

Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)CLU(27457297)-PEBP1(118575844), # samples:1
Anticipated loss of major functional domain due to fusion event.CLU-PEBP1 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
CLU-PEBP1 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
CLU-PEBP1 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
CLU-PEBP1 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
CLU-PEBP1 seems lost the major protein functional domain in Hgene partner, which is a tumor suppressor due to the frame-shifted ORF.
CLU-PEBP1 seems lost the major protein functional domain in Tgene partner, which is a tumor suppressor due to the frame-shifted ORF.
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

check button Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez
PartnerGeneGO IDGO termPubMed ID
HgeneCLU

GO:0000902

cell morphogenesis

15857407

HgeneCLU

GO:0001774

microglial cell activation

15857407

HgeneCLU

GO:0017038

protein import

24446231

HgeneCLU

GO:0031333

negative regulation of protein complex assembly

22179788|23106396

HgeneCLU

GO:0031334

positive regulation of protein complex assembly

22179788

HgeneCLU

GO:0032760

positive regulation of tumor necrosis factor production

15857407

HgeneCLU

GO:0045429

positive regulation of nitric oxide biosynthetic process

15857407

HgeneCLU

GO:0050821

protein stabilization

11123922|12176985

HgeneCLU

GO:0051131

chaperone-mediated protein complex assembly

17412999

HgeneCLU

GO:0051788

response to misfolded protein

19996109

HgeneCLU

GO:0061077

chaperone-mediated protein folding

11123922

HgeneCLU

GO:0061518

microglial cell proliferation

15857407

HgeneCLU

GO:1900221

regulation of amyloid-beta clearance

24446231

HgeneCLU

GO:1901214

regulation of neuron death

17412999

HgeneCLU

GO:1901216

positive regulation of neuron death

15857407

HgeneCLU

GO:1902430

negative regulation of amyloid-beta formation

12047389|17412999

HgeneCLU

GO:1905907

negative regulation of amyloid fibril formation

22179788



check button Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr8:27457297/chr12:118575844)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.
FGviewer

check buttonRetention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

check buttonFusion gene breakpoints across CLU (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure

check buttonFusion gene breakpoints across PEBP1 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure


Top

Fusion Amino Acid Sequences


check buttonFusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandSeq length
(transcript)
BP loci
(transcript)
Predicted start
(transcript)
Predicted stop
(transcript)
Seq length
(amino acids)
ENST00000546343CLUchr827457297-ENST00000261313PEBP1chr12118575844+255413441471772541
ENST00000560366CLUchr827457297-ENST00000261313PEBP1chr12118575844+25591349291777582
ENST00000523500CLUchr827457297-ENST00000261313PEBP1chr12118575844+316019506812378565

check buttonDeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandNo-coding scoreCoding score
ENST00000546343ENST00000261313CLUchr827457297-PEBP1chr12118575844+0.0031230530.99687696
ENST00000560366ENST00000261313CLUchr827457297-PEBP1chr12118575844+0.0017775930.9982224
ENST00000523500ENST00000261313CLUchr827457297-PEBP1chr12118575844+0.0025373660.99746263

check button Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for CLU-PEBP1

check button +/-13 AA sequence from the breakpoints of the fusion protein sequences.
HgeneHchrHbpTgeneTchrTbpLength(fusion protein)BP in fusion proteinPeptide
CLUchr827457297PEBP1chr121185758441344399TQGEDQYYLRVTTVKNRPTSISWDGL
CLUchr827457297PEBP1chr121185758441349440TQGEDQYYLRVTTVKNRPTSISWDGL
CLUchr827457297PEBP1chr121185758441950423TQGEDQYYLRVTTVKNRPTSISWDGL

Top

Potential FusionNeoAntigen Information of CLU-PEBP1 in HLA I

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
CLU-PEBP1_27457297_118575844.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)
Fusion geneHchrHbpTgeneTchrTbpHLA IFusionNeoAntigen peptideBinding scoreImmunogenic scoreNeoantigen start (at BP 13)Neoantigen end (at BP 13)
CLU-PEBP1chr827457297chr121185758441950HLA-B08:01QYYLRVTTV0.9740.6942514
CLU-PEBP1chr827457297chr121185758441950HLA-A30:08TVKNRPTSI0.97130.67321221
CLU-PEBP1chr827457297chr121185758441950HLA-B08:09QYYLRVTTV0.96950.7758514
CLU-PEBP1chr827457297chr121185758441950HLA-B14:01QYYLRVTTV0.94570.7566514
CLU-PEBP1chr827457297chr121185758441950HLA-B14:02QYYLRVTTV0.94570.7566514
CLU-PEBP1chr827457297chr121185758441950HLA-B14:01TVKNRPTSI0.92440.61121221
CLU-PEBP1chr827457297chr121185758441950HLA-B14:02TVKNRPTSI0.92440.61121221
CLU-PEBP1chr827457297chr121185758441950HLA-A24:14QYYLRVTTV0.77710.5599514
CLU-PEBP1chr827457297chr121185758441950HLA-A31:08QYYLRVTTV0.68530.5794514
CLU-PEBP1chr827457297chr121185758441950HLA-B52:01QYYLRVTTV0.28290.8537514
CLU-PEBP1chr827457297chr121185758441950HLA-B57:01TVKNRPTSISW0.99990.96881223
CLU-PEBP1chr827457297chr121185758441950HLA-B58:02TVKNRPTSISW0.99960.93121223
CLU-PEBP1chr827457297chr121185758441950HLA-B15:17TVKNRPTSISW0.99720.92431223
CLU-PEBP1chr827457297chr121185758441950HLA-B58:01TVKNRPTSISW0.99420.92661223
CLU-PEBP1chr827457297chr121185758441950HLA-B57:03TVKNRPTSISW0.99290.98271223
CLU-PEBP1chr827457297chr121185758441950HLA-A32:13TVKNRPTSISW0.9540.97911223
CLU-PEBP1chr827457297chr121185758441950HLA-C04:14YYLRVTTV0.95510.8844614
CLU-PEBP1chr827457297chr121185758441950HLA-C12:04TVKNRPTSI0.99020.97781221
CLU-PEBP1chr827457297chr121185758441950HLA-C06:03TVKNRPTSI0.98970.96591221
CLU-PEBP1chr827457297chr121185758441950HLA-C12:12TVKNRPTSI0.97570.81951221
CLU-PEBP1chr827457297chr121185758441950HLA-B14:03TVKNRPTSI0.82390.62361221
CLU-PEBP1chr827457297chr121185758441950HLA-B14:03QYYLRVTTV0.49990.7524514
CLU-PEBP1chr827457297chr121185758441950HLA-C07:05QYYLRVTTV0.4570.9759514
CLU-PEBP1chr827457297chr121185758441950HLA-C07:19QYYLRVTTV0.4150.7875514
CLU-PEBP1chr827457297chr121185758441950HLA-C07:67QYYLRVTTV0.38570.9556514
CLU-PEBP1chr827457297chr121185758441950HLA-C07:80QYYLRVTTV0.38570.9556514
CLU-PEBP1chr827457297chr121185758441950HLA-C07:46QYYLRVTTV0.36620.8724514
CLU-PEBP1chr827457297chr121185758441950HLA-C07:29QYYLRVTTV0.34930.926514
CLU-PEBP1chr827457297chr121185758441950HLA-C07:10QYYLRVTTV0.33220.9622514
CLU-PEBP1chr827457297chr121185758441950HLA-C07:13QYYLRVTTV0.27670.927514
CLU-PEBP1chr827457297chr121185758441950HLA-B39:12QYYLRVTTV0.22570.8502514
CLU-PEBP1chr827457297chr121185758441950HLA-C12:16QYYLRVTTV0.19580.9766514
CLU-PEBP1chr827457297chr121185758441950HLA-C07:27QYYLRVTTV0.17870.9599514
CLU-PEBP1chr827457297chr121185758441950HLA-B51:07DQYYLRVTTV0.9220.6609414
CLU-PEBP1chr827457297chr121185758441950HLA-C04:04YYLRVTTV0.94650.9638614
CLU-PEBP1chr827457297chr121185758441950HLA-C06:06YYLRVTTV0.86960.9906614
CLU-PEBP1chr827457297chr121185758441950HLA-C14:02YYLRVTTV0.62480.9716614
CLU-PEBP1chr827457297chr121185758441950HLA-C14:03YYLRVTTV0.62480.9716614
CLU-PEBP1chr827457297chr121185758441950HLA-C06:02TVKNRPTSI0.98790.97441221
CLU-PEBP1chr827457297chr121185758441950HLA-C06:17TVKNRPTSI0.98790.97441221
CLU-PEBP1chr827457297chr121185758441950HLA-A30:01TVKNRPTSI0.97610.75351221
CLU-PEBP1chr827457297chr121185758441950HLA-C12:03TVKNRPTSI0.97420.91921221
CLU-PEBP1chr827457297chr121185758441950HLA-B08:18QYYLRVTTV0.9740.6942514
CLU-PEBP1chr827457297chr121185758441950HLA-B08:12QYYLRVTTV0.9040.8071514
CLU-PEBP1chr827457297chr121185758441950HLA-C07:04TVKNRPTSI0.78060.87561221
CLU-PEBP1chr827457297chr121185758441950HLA-C06:17QYYLRVTTV0.63950.9941514
CLU-PEBP1chr827457297chr121185758441950HLA-C06:02QYYLRVTTV0.63950.9941514
CLU-PEBP1chr827457297chr121185758441950HLA-C04:04QYYLRVTTV0.54270.9251514
CLU-PEBP1chr827457297chr121185758441950HLA-C06:08QYYLRVTTV0.42520.9909514
CLU-PEBP1chr827457297chr121185758441950HLA-C07:04QYYLRVTTV0.41080.9637514
CLU-PEBP1chr827457297chr121185758441950HLA-C07:02QYYLRVTTV0.38570.9556514
CLU-PEBP1chr827457297chr121185758441950HLA-C07:17QYYLRVTTV0.35740.9739514
CLU-PEBP1chr827457297chr121185758441950HLA-C03:67QYYLRVTTV0.21060.9818514
CLU-PEBP1chr827457297chr121185758441950HLA-C06:06QYYLRVTTV0.18490.9906514
CLU-PEBP1chr827457297chr121185758441950HLA-C07:01QYYLRVTTV0.14480.7175514
CLU-PEBP1chr827457297chr121185758441950HLA-C14:03QYYLRVTTV0.08780.979514
CLU-PEBP1chr827457297chr121185758441950HLA-C14:02QYYLRVTTV0.08780.979514
CLU-PEBP1chr827457297chr121185758441950HLA-B57:10TVKNRPTSISW0.99990.96881223
CLU-PEBP1chr827457297chr121185758441950HLA-B57:04TVKNRPTSISW0.99980.75161223
CLU-PEBP1chr827457297chr121185758441950HLA-B58:06TVKNRPTSISW0.99930.91211223
CLU-PEBP1chr827457297chr121185758441950HLA-B15:24TVKNRPTSISW0.9990.95421223
CLU-PEBP1chr827457297chr121185758441950HLA-B57:02TVKNRPTSISW0.99690.96051223
CLU-PEBP1chr827457297chr121185758441950HLA-B15:13TVKNRPTSISW0.99030.7471223
CLU-PEBP1chr827457297chr121185758441950HLA-A32:01TVKNRPTSISW0.98780.98021223
CLU-PEBP1chr827457297chr121185758441950HLA-A25:01TVKNRPTSISW0.82160.94811223

Top

Potential FusionNeoAntigen Information of CLU-PEBP1 in HLA II

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
CLU-PEBP1_27457297_118575844.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).
Fusion geneHchrHbpTgeneTchrTbpHLA IIFusionNeoAntigen peptideNeoantigen start (at BP 13)Neoantigen end (at BP 13)
CLU-PEBP1chr827457297chr121185758441950DRB1-0113DQYYLRVTTVKNRPT419
CLU-PEBP1chr827457297chr121185758441950DRB1-0401DQYYLRVTTVKNRPT419
CLU-PEBP1chr827457297chr121185758441950DRB1-0401EDQYYLRVTTVKNRP318
CLU-PEBP1chr827457297chr121185758441950DRB1-0407DQYYLRVTTVKNRPT419
CLU-PEBP1chr827457297chr121185758441950DRB1-0407EDQYYLRVTTVKNRP318
CLU-PEBP1chr827457297chr121185758441950DRB1-0417DQYYLRVTTVKNRPT419
CLU-PEBP1chr827457297chr121185758441950DRB1-0417EDQYYLRVTTVKNRP318
CLU-PEBP1chr827457297chr121185758441950DRB1-0419DQYYLRVTTVKNRPT419
CLU-PEBP1chr827457297chr121185758441950DRB1-0419EDQYYLRVTTVKNRP318
CLU-PEBP1chr827457297chr121185758441950DRB1-0424DQYYLRVTTVKNRPT419
CLU-PEBP1chr827457297chr121185758441950DRB1-0424EDQYYLRVTTVKNRP318
CLU-PEBP1chr827457297chr121185758441950DRB1-0431DQYYLRVTTVKNRPT419
CLU-PEBP1chr827457297chr121185758441950DRB1-0431EDQYYLRVTTVKNRP318
CLU-PEBP1chr827457297chr121185758441950DRB1-0433DQYYLRVTTVKNRPT419
CLU-PEBP1chr827457297chr121185758441950DRB1-0433EDQYYLRVTTVKNRP318
CLU-PEBP1chr827457297chr121185758441950DRB1-0434DQYYLRVTTVKNRPT419
CLU-PEBP1chr827457297chr121185758441950DRB1-0434EDQYYLRVTTVKNRP318
CLU-PEBP1chr827457297chr121185758441950DRB1-0435DQYYLRVTTVKNRPT419
CLU-PEBP1chr827457297chr121185758441950DRB1-0435EDQYYLRVTTVKNRP318
CLU-PEBP1chr827457297chr121185758441950DRB1-0437VTTVKNRPTSISWDG1025
CLU-PEBP1chr827457297chr121185758441950DRB1-0438DQYYLRVTTVKNRPT419
CLU-PEBP1chr827457297chr121185758441950DRB1-0438EDQYYLRVTTVKNRP318
CLU-PEBP1chr827457297chr121185758441950DRB1-0443DQYYLRVTTVKNRPT419
CLU-PEBP1chr827457297chr121185758441950DRB1-0443EDQYYLRVTTVKNRP318
CLU-PEBP1chr827457297chr121185758441950DRB1-0447DQYYLRVTTVKNRPT419
CLU-PEBP1chr827457297chr121185758441950DRB1-0447EDQYYLRVTTVKNRP318
CLU-PEBP1chr827457297chr121185758441950DRB1-0447GEDQYYLRVTTVKNR217
CLU-PEBP1chr827457297chr121185758441950DRB1-0447QYYLRVTTVKNRPTS520
CLU-PEBP1chr827457297chr121185758441950DRB1-0454DQYYLRVTTVKNRPT419
CLU-PEBP1chr827457297chr121185758441950DRB1-0454EDQYYLRVTTVKNRP318
CLU-PEBP1chr827457297chr121185758441950DRB1-0454GEDQYYLRVTTVKNR217
CLU-PEBP1chr827457297chr121185758441950DRB1-0454QYYLRVTTVKNRPTS520
CLU-PEBP1chr827457297chr121185758441950DRB1-0461DQYYLRVTTVKNRPT419
CLU-PEBP1chr827457297chr121185758441950DRB1-0461EDQYYLRVTTVKNRP318
CLU-PEBP1chr827457297chr121185758441950DRB1-0462DQYYLRVTTVKNRPT419
CLU-PEBP1chr827457297chr121185758441950DRB1-0462EDQYYLRVTTVKNRP318
CLU-PEBP1chr827457297chr121185758441950DRB1-0463DQYYLRVTTVKNRPT419
CLU-PEBP1chr827457297chr121185758441950DRB1-0463EDQYYLRVTTVKNRP318
CLU-PEBP1chr827457297chr121185758441950DRB1-0464DQYYLRVTTVKNRPT419
CLU-PEBP1chr827457297chr121185758441950DRB1-0464EDQYYLRVTTVKNRP318
CLU-PEBP1chr827457297chr121185758441950DRB1-0469DQYYLRVTTVKNRPT419
CLU-PEBP1chr827457297chr121185758441950DRB1-0469EDQYYLRVTTVKNRP318
CLU-PEBP1chr827457297chr121185758441950DRB1-0472DQYYLRVTTVKNRPT419
CLU-PEBP1chr827457297chr121185758441950DRB1-0474DQYYLRVTTVKNRPT419
CLU-PEBP1chr827457297chr121185758441950DRB1-0474EDQYYLRVTTVKNRP318
CLU-PEBP1chr827457297chr121185758441950DRB1-0475DQYYLRVTTVKNRPT419
CLU-PEBP1chr827457297chr121185758441950DRB1-0475EDQYYLRVTTVKNRP318
CLU-PEBP1chr827457297chr121185758441950DRB1-0476DQYYLRVTTVKNRPT419
CLU-PEBP1chr827457297chr121185758441950DRB1-0476EDQYYLRVTTVKNRP318
CLU-PEBP1chr827457297chr121185758441950DRB1-0480DQYYLRVTTVKNRPT419
CLU-PEBP1chr827457297chr121185758441950DRB1-0480EDQYYLRVTTVKNRP318
CLU-PEBP1chr827457297chr121185758441950DRB1-0482DQYYLRVTTVKNRPT419
CLU-PEBP1chr827457297chr121185758441950DRB1-0482EDQYYLRVTTVKNRP318
CLU-PEBP1chr827457297chr121185758441950DRB1-0486DQYYLRVTTVKNRPT419
CLU-PEBP1chr827457297chr121185758441950DRB1-0486EDQYYLRVTTVKNRP318
CLU-PEBP1chr827457297chr121185758441950DRB1-0486GEDQYYLRVTTVKNR217
CLU-PEBP1chr827457297chr121185758441950DRB1-0487DQYYLRVTTVKNRPT419
CLU-PEBP1chr827457297chr121185758441950DRB1-0813EDQYYLRVTTVKNRP318
CLU-PEBP1chr827457297chr121185758441950DRB1-0813DQYYLRVTTVKNRPT419
CLU-PEBP1chr827457297chr121185758441950DRB1-0815EDQYYLRVTTVKNRP318
CLU-PEBP1chr827457297chr121185758441950DRB1-0815DQYYLRVTTVKNRPT419
CLU-PEBP1chr827457297chr121185758441950DRB1-0830EDQYYLRVTTVKNRP318
CLU-PEBP1chr827457297chr121185758441950DRB1-0830DQYYLRVTTVKNRPT419
CLU-PEBP1chr827457297chr121185758441950DRB1-0832EDQYYLRVTTVKNRP318
CLU-PEBP1chr827457297chr121185758441950DRB1-0832DQYYLRVTTVKNRPT419
CLU-PEBP1chr827457297chr121185758441950DRB1-0837EDQYYLRVTTVKNRP318
CLU-PEBP1chr827457297chr121185758441950DRB1-0902DQYYLRVTTVKNRPT419
CLU-PEBP1chr827457297chr121185758441950DRB1-1001DQYYLRVTTVKNRPT419
CLU-PEBP1chr827457297chr121185758441950DRB1-1001EDQYYLRVTTVKNRP318
CLU-PEBP1chr827457297chr121185758441950DRB1-1001GEDQYYLRVTTVKNR217
CLU-PEBP1chr827457297chr121185758441950DRB1-1001QYYLRVTTVKNRPTS520
CLU-PEBP1chr827457297chr121185758441950DRB1-1003DQYYLRVTTVKNRPT419
CLU-PEBP1chr827457297chr121185758441950DRB1-1003EDQYYLRVTTVKNRP318
CLU-PEBP1chr827457297chr121185758441950DRB1-1003GEDQYYLRVTTVKNR217
CLU-PEBP1chr827457297chr121185758441950DRB1-1003QYYLRVTTVKNRPTS520
CLU-PEBP1chr827457297chr121185758441950DRB1-1130DQYYLRVTTVKNRPT419
CLU-PEBP1chr827457297chr121185758441950DRB1-1130EDQYYLRVTTVKNRP318
CLU-PEBP1chr827457297chr121185758441950DRB1-1145EDQYYLRVTTVKNRP318
CLU-PEBP1chr827457297chr121185758441950DRB1-1367EDQYYLRVTTVKNRP318
CLU-PEBP1chr827457297chr121185758441950DRB1-1367DQYYLRVTTVKNRPT419
CLU-PEBP1chr827457297chr121185758441950DRB1-1403EDQYYLRVTTVKNRP318
CLU-PEBP1chr827457297chr121185758441950DRB1-1403DQYYLRVTTVKNRPT419
CLU-PEBP1chr827457297chr121185758441950DRB1-1440EDQYYLRVTTVKNRP318
CLU-PEBP1chr827457297chr121185758441950DRB1-1440DQYYLRVTTVKNRPT419
CLU-PEBP1chr827457297chr121185758441950DRB1-1446DQYYLRVTTVKNRPT419
CLU-PEBP1chr827457297chr121185758441950DRB1-1446EDQYYLRVTTVKNRP318
CLU-PEBP1chr827457297chr121185758441950DRB1-1467EDQYYLRVTTVKNRP318
CLU-PEBP1chr827457297chr121185758441950DRB1-1467DQYYLRVTTVKNRPT419
CLU-PEBP1chr827457297chr121185758441950DRB1-1477EDQYYLRVTTVKNRP318
CLU-PEBP1chr827457297chr121185758441950DRB1-1477DQYYLRVTTVKNRPT419
CLU-PEBP1chr827457297chr121185758441950DRB1-1489EDQYYLRVTTVKNRP318
CLU-PEBP1chr827457297chr121185758441950DRB1-1498EDQYYLRVTTVKNRP318
CLU-PEBP1chr827457297chr121185758441950DRB1-1498DQYYLRVTTVKNRPT419
CLU-PEBP1chr827457297chr121185758441950DRB3-0217DQYYLRVTTVKNRPT419
CLU-PEBP1chr827457297chr121185758441950DRB5-0102EDQYYLRVTTVKNRP318
CLU-PEBP1chr827457297chr121185758441950DRB5-0102DQYYLRVTTVKNRPT419
CLU-PEBP1chr827457297chr121185758441950DRB5-0103EDQYYLRVTTVKNRP318
CLU-PEBP1chr827457297chr121185758441950DRB5-0103GEDQYYLRVTTVKNR217
CLU-PEBP1chr827457297chr121185758441950DRB5-0103DQYYLRVTTVKNRPT419
CLU-PEBP1chr827457297chr121185758441950DRB5-0104EDQYYLRVTTVKNRP318
CLU-PEBP1chr827457297chr121185758441950DRB5-0108NEDQYYLRVTTVKNRP318
CLU-PEBP1chr827457297chr121185758441950DRB5-0108NDQYYLRVTTVKNRPT419

Top

Fusion breakpoint peptide structures of CLU-PEBP1

check button3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.
File nameBPseqHgeneTgeneHchrHbpTchrTbpAAlen
10866YYLRVTTVKNRPTSCLUPEBP1chr827457297chr121185758441950

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of CLU-PEBP1

check buttonVirtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.
HLA allelePDB IDFile nameBPseqDocking scoreGlide score
HLA-B14:023BVN10866YYLRVTTVKNRPTS-8.62545-8.73885
HLA-B14:023BVN10866YYLRVTTVKNRPTS-3.26321-4.29851
HLA-B52:013W3910866YYLRVTTVKNRPTS-6.23413-6.34753
HLA-B52:013W3910866YYLRVTTVKNRPTS-4.55402-5.58932
HLA-A24:025HGA10866YYLRVTTVKNRPTS-8.62578-8.73918
HLA-A24:025HGA10866YYLRVTTVKNRPTS-6.438-7.4733
HLA-B44:053DX810866YYLRVTTVKNRPTS-5.68484-5.79824
HLA-B44:053DX810866YYLRVTTVKNRPTS-3.64855-4.68385
HLA-A02:016TDR10866YYLRVTTVKNRPTS-5.14764-6.18294

Top

Vaccine Design for the FusionNeoAntigens of CLU-PEBP1

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptide sequenceFusionNeoAntigen RNA sequence
CLU-PEBP1chr827457297chr121185758441221TVKNRPTSIACGGTTAAGAATAGACCCACCAGCATT
CLU-PEBP1chr827457297chr121185758441223TVKNRPTSISWACGGTTAAGAATAGACCCACCAGCATTTCGTGG
CLU-PEBP1chr827457297chr12118575844414DQYYLRVTTVGACCAGTACTATCTGCGGGTCACCACGGTT
CLU-PEBP1chr827457297chr12118575844514QYYLRVTTVCAGTACTATCTGCGGGTCACCACGGTT
CLU-PEBP1chr827457297chr12118575844614YYLRVTTVTACTATCTGCGGGTCACCACGGTT

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptideFusionNEoAntigen RNA sequence
CLU-PEBP1chr827457297chr121185758441025VTTVKNRPTSISWDGGTCACCACGGTTAAGAATAGACCCACCAGCATTTCGTGGGATGGT
CLU-PEBP1chr827457297chr12118575844217GEDQYYLRVTTVKNRGGCGAAGACCAGTACTATCTGCGGGTCACCACGGTTAAGAATAGA
CLU-PEBP1chr827457297chr12118575844318EDQYYLRVTTVKNRPGAAGACCAGTACTATCTGCGGGTCACCACGGTTAAGAATAGACCC
CLU-PEBP1chr827457297chr12118575844419DQYYLRVTTVKNRPTGACCAGTACTATCTGCGGGTCACCACGGTTAAGAATAGACCCACC
CLU-PEBP1chr827457297chr12118575844520QYYLRVTTVKNRPTSCAGTACTATCTGCGGGTCACCACGGTTAAGAATAGACCCACCAGC

Top

Information of the samples that have these potential fusion neoantigens of CLU-PEBP1

check button These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.
Cancer typeFusion geneHchrHbpHenstTchrTbpTenstSample
LGGCLU-PEBP1chr827457297ENST00000523500chr12118575844ENST00000261313TCGA-QH-A6CS-01A

Top

Potential target of CAR-T therapy development for CLU-PEBP1

check button Predicted 3D structure. We used RoseTTAFold.

check buttonRetention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features


* Minus value of BPloci means that the break point is located before the CDS.
- In-frame and retained 'Transmembrane'.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note

check button Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.
HgeneHchrHbpHenstTgeneTchrTbpTenstDeepLoc result

Top

Related Drugs to CLU-PEBP1

check button Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDrugSourcePMID

Top

Related Diseases to CLU-PEBP1

check button Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDiseaseSourcePMID

check button Diseases associated with fusion partners.
(DisGeNet 4.0)
PartnerGeneDisease IDDisease name# pubmedsSource
HgeneCLUC0022660Kidney Failure, Acute6CTD_human
HgeneCLUC1565662Acute Kidney Insufficiency6CTD_human
HgeneCLUC2609414Acute kidney injury6CTD_human
HgeneCLUC0002395Alzheimer's Disease3CTD_human
HgeneCLUC0011265Presenile dementia3CTD_human
HgeneCLUC0022658Kidney Diseases3CTD_human
HgeneCLUC0276496Familial Alzheimer Disease (FAD)3CTD_human
HgeneCLUC0494463Alzheimer Disease, Late Onset3CTD_human
HgeneCLUC0546126Acute Confusional Senile Dementia3CTD_human
HgeneCLUC0750900Alzheimer's Disease, Focal Onset3CTD_human
HgeneCLUC0750901Alzheimer Disease, Early Onset3CTD_human
HgeneCLUC0013221Drug toxicity2CTD_human
HgeneCLUC0029408Degenerative polyarthritis2CTD_human
HgeneCLUC0041755Adverse reaction to drug2CTD_human
HgeneCLUC0086743Osteoarthrosis Deformans2CTD_human
HgeneCLUC0019193Hepatitis, Toxic1CTD_human
HgeneCLUC0022333Jacksonian Seizure1CTD_human
HgeneCLUC0024141Lupus Erythematosus, Systemic1CTD_human
HgeneCLUC0025202melanoma1CTD_human
HgeneCLUC0027686Pathologic Neovascularization1CTD_human
HgeneCLUC0033578Prostatic Neoplasms1CTD_human
HgeneCLUC0036341Schizophrenia1PSYGENET
HgeneCLUC0036572Seizures1CTD_human
HgeneCLUC0087031Juvenile-Onset Still Disease1CTD_human
HgeneCLUC0149958Complex partial seizures1CTD_human
HgeneCLUC0234533Generalized seizures1CTD_human
HgeneCLUC0234535Clonic Seizures1CTD_human
HgeneCLUC0234985Mental deterioration1CTD_human
HgeneCLUC0242380Libman-Sacks Disease1CTD_human
HgeneCLUC0270824Visual seizure1CTD_human
HgeneCLUC0270844Tonic Seizures1CTD_human
HgeneCLUC0270846Epileptic drop attack1CTD_human
HgeneCLUC0333641Atrophic1CTD_human
HgeneCLUC0338656Impaired cognition1CTD_human
HgeneCLUC0376358Malignant neoplasm of prostate1CTD_human
HgeneCLUC0422850Seizures, Somatosensory1CTD_human
HgeneCLUC0422852Seizures, Auditory1CTD_human
HgeneCLUC0422853Olfactory seizure1CTD_human
HgeneCLUC0422854Gustatory seizure1CTD_human
HgeneCLUC0422855Vertiginous seizure1CTD_human
HgeneCLUC0494475Tonic - clonic seizures1CTD_human
HgeneCLUC0751056Non-epileptic convulsion1CTD_human
HgeneCLUC0751110Single Seizure1CTD_human
HgeneCLUC0751123Atonic Absence Seizures1CTD_human
HgeneCLUC0751494Convulsive Seizures1CTD_human
HgeneCLUC0751495Seizures, Focal1CTD_human
HgeneCLUC0751496Seizures, Sensory1CTD_human
HgeneCLUC0860207Drug-Induced Liver Disease1CTD_human
HgeneCLUC1262760Hepatitis, Drug-Induced1CTD_human
HgeneCLUC1270972Mild cognitive disorder1CTD_human
HgeneCLUC1862939AMYOTROPHIC LATERAL SCLEROSIS 11CTD_human
HgeneCLUC1862941Amyotrophic Lateral Sclerosis, Sporadic1CTD_human
HgeneCLUC3495559Juvenile arthritis1CTD_human
HgeneCLUC3495874Nonepileptic Seizures1CTD_human
HgeneCLUC3658290Drug-Induced Acute Liver Injury1CTD_human
HgeneCLUC3714758Juvenile psoriatic arthritis1CTD_human
HgeneCLUC4048158Convulsions1CTD_human
HgeneCLUC4277682Chemical and Drug Induced Liver Injury1CTD_human
HgeneCLUC4279912Chemically-Induced Liver Toxicity1CTD_human
HgeneCLUC4316903Absence Seizures1CTD_human
HgeneCLUC4317109Epileptic Seizures1CTD_human
HgeneCLUC4317123Myoclonic Seizures1CTD_human
HgeneCLUC4505436Generalized Absence Seizures1CTD_human
HgeneCLUC4551993Amyotrophic Lateral Sclerosis, Familial1CTD_human
HgeneCLUC4552091Polyarthritis, Juvenile, Rheumatoid Factor Negative1CTD_human
HgeneCLUC4704862Polyarthritis, Juvenile, Rheumatoid Factor Positive1CTD_human